Tenecteplase Unseats Low-Dose Alteplase Favored for Asian Patients

(MedPage Today) -- Standard-dose tenecteplase (TNKase) beat low-dose alteplase as a bridge to stroke thrombectomy in bleeding-prone patients, a Japanese trial found. Early reperfusion outcomes significantly favored patients who received tenecteplase...
Source
MedPage Today
Opens original article in a new tab



